Welcome everyone to the Fresh Tracks Therapeutics third quarter 2022 financial results conference call. At this time, all participants are in a listen-only mode. Following some prepared remarks from the company, we will open the call up to questions. As a reminder, this conference call is being recorded. I would now like to turn the call over to Garth Russell from LifeSci Advisors. Garth. Thank you, and good afternoon, everyone. Joining me on today's call are Fresh Tracks Therapeutics Chief Executive Officer, Rob Brown, President, Andrew Sklawer, Chief Financial Officer, Albert Marchio, Chief Medical Officer, Dr. Monica Luchi, Chief R&D Officer and Chief Operating Officer, Deepa Chadha. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of the date of this call. We will not undertake obligation to revise or publicly release the results of any revisions to these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and our other periodic reports on Forms 10-Q and 8-K filed with the SEC. It is now my pleasure to turn the call over to the company's Chief Executive Officer, Robert Brown. Rob, the floor is yours. Thanks, Garth. Good afternoon, everyone, and thank you for joining our call today. This is the first quarterly update since we completed our corporate rebranding this summer, which included the introduction of our new company name, Fresh Tracks Therapeutics, along with a new logo, website, and brand. We believe this rebranding represents the fundamental shift we've made over the past year in our corporate mission and strategy. Driving these changes were the acquisitions of a promising pipeline of NCEs targeting novel mechanisms of actions for the treatment of a wide array of autoimmune and inflammatory diseases. This is highlighted by FRTX-02, formerly BBI-02, a potential first-in-class DYRK1A inhibitor that is currently being evaluated in a phase I clinical trial. FRTX-10, formerly BBI-10, a novel STING inhibitor and a platform of Next- Generation Kinase inhibitors. These programs highlight our commitment to shift treatment paradigms by developing targeted, science-driven, and potentially first-in-class therapies that could transform patients' lives while generating meaningful value for our shareholders. During the third quarter, we continued to progress the phase I clinical trial of FRTX-02. This includes completion of all cohorts of the Single Ascending Dose, SAD or SAD, part of the study, and initiation of the Multiple Ascending Dose, MAD or Mad, part of the study. Currently, we remain on track to report SAD and MAD top-line results by early 2023. As a reminder, this study marks the first time a DYRK1A inhibitor intended for patients with autoimmune disease has been orally administered in humans. In addition, we continue to advance the non-clinical development program for FRTX-02 in parallel with the ongoing phase I study. As well as pre-clinical development activities for FRTX-10, which is our lead STING inhibitor candidate that we acquired earlier this year. Finally, I'd like to provide a brief update on sofpironium bromide or SB for short, which we sold to Botanix this past May. As Botanix recently announced in September, a new drug application or NDA for SB gel, 15% was submitted to the FDA. We are excited to share this progress. As a reminder, under the terms of our sale of SB to Botanix, Fresh Tracks is eligible to receive various regulatory and sales-based milestone payments, as well as tiered earn-out payments ranging from high single digits to mid-teen digits on net sales of SB gel. We look forward to sharing any additional updates regarding this program as they become available. Now I'll pass it over to Monica to provide an update on our ongoing pipeline development activities. Monica. Thanks, Rob, and good afternoon, everyone. We've had a very productive third quarter of 2022, which built on the momentum from the first half of this year. As Rob just mentioned, during the second quarter, we initiated and are continuing to progress the phase I clinical trial of FRTX-02, our potent, highly selective, and orally bioavailable DYRK1A inhibitor. This randomized, double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of FRTX-02 capsules in both healthy volunteers and subjects with atopic dermatitis, or AD for short. As a reminder, based on the scientifically robust data package and promising preclinical validation that's been observed with this compound to date, we believe that FRTX's dual mode of action modulating both the adaptive and innate immune systems could represent a paradigm shift in the way we currently treat these debilitating diseases. Part 1-A of the phase I study, which has been completed, is a SAD assessment, which has enrolled a total of 56 healthy volunteers at one study center across seven cohorts, each of which included six subjects receiving a single dose of FRTX-02 and two subjects receiving a placebo. Based on the profile of FRTX-02 observed in the SAD part of the study, in September, we initiated Part 1-B of the study, which is a MAD assessment of FRTX-02 capsules or placebo administered once daily over 14 days in up to 33 healthy volunteers. We look forward to reporting top-line results from both the SAD and the MAD parts of the study by early next year. After completing the SAD and MAD parts of the study, we intend to initiate part two of the study, which will compare the FRTX-02 to placebo in approximately 40 patients with moderate to severe atopic dermatitis over 28 days of dosing. This part of the study is expected to include a preliminary assessment of efficacy, which will serve as an initial model for the treatment of FRTX-02 in immune-mediated disease. This design fits with our broader strategy for this program, considering the potential to develop FRTX-02 for the treatment of a wide range of autoimmune and inflammatory diseases. Turning to our STING inhibitor program, FRTX-10, which is a novel, potent, and orally bioavailable STING inhibitor. FRTX-10 has shown strong proof of mechanism resulting in significant reduction in key pro-inflammatory cytokines and a favorable initial pharmacokinetic, toxicology, and safety pharmacology profile. We continue to advance the preclinical development activities for this program to support starting IND-enabling studies thereafter. I'd also like to briefly touch on our library of next-generation kinase inhibitors, which includes hundreds of new chemical entities that inhibit DYRK1, LRRK2, TTK, and CLK kinases. Importantly, inhibiting these kinases has shown promising outcomes in numerous models designed to mimic a range of different conditions within the autoimmune, neuroinflammatory, oncology, and rare disease spaces. We're planning to identify, characterize, and optimize both brain-penetrant and non-brain-penetrant novel kinase inhibitors from this platform with the goal of progressing one or more as programs for the potential treatment of debilitating diseases within some of these high-impact fields. Before I hand the call over to Bert to review the financials, I'd like to highlight the recent formation of our Scientific Advisory Board or SAB, which consists of five scientists and clinicians with decades of hands-on experience in the fields of immunology and inflammation. This includes doctors Katherine Fitzgerald, Bernard Khor, Pui Lee, Peter Nigrovic, and Denisa Wagner. We're honored to welcome this team of world-renowned thought leaders to our newly established SAB, whose input and guidance will be invaluable as we develop our novel pipeline of differentiated therapies. I'd now like to pass the call over to Bert to provide a financial overview for the quarter. Bert? Thanks, Monica, and good day to everyone on the call. Before I provide a summary of the third quarter 2022 financial results, I want to encourage you to read our full consolidated financial statements and MD&A contained in our report on Form 10-Q, which can be accessed through the investors section of our website once filed with the SEC. Starting with cash, the company reported $11.3 million in cash and cash equivalents as of September 30, 2022. We expect that our cash and cash equivalents, combined with up to $6 million from the expected near-term payments under the asset purchase agreement or APA with Botanix, will be sufficient to fund our operations for at least the next 12 months. Revenue for the third quarter of 2022 was approximately $0.5 million compared to $0.1 million for the third quarter of the prior year. Revenue for the third quarter of this year consisted of contract revenue recognized under the APA and transition services agreement or TSA with Botanix, which includes $0.4 million of fees for consulting services the company provided to Botanix under the TSA and sublicense income under the APA of $0.1 million. Revenue for the same period last year consisted of royalty revenue we recognized from the sales of ECCLOCK or SB gel 5% in Japan by Kaken Pharmaceutical. R&D expenses were $3.6 million for the third quarter of 2022 compared to $10.2 million for the third quarter of 2021. This decrease was driven primarily by lower clinical expenses related to SB, upfront license expense incurred in connection with the license agreement with Voronoi Inc, and lower regulatory and compliance fees, partially offset by the phase I clinical trial costs for FRTX-02. G&A expenses were $3 million for the third quarter of 2022 compared to $3.3 million for the same quarter of the prior year, which decrease was primarily related to lower compensation expenses and other administrative fees. The company's net loss for the third quarter was $6 million compared to $13.3 million for the third quarter of last year. With that, I'll turn the call back over to Rob for closing remarks. Rob? Thanks for the financial recap, Burt. We're pleased with the progress over the first nine months of 2022, and we look forward to continuing the advancement of our exciting pipeline of novel therapies. We believe this pipeline has broad potential to produce much needed treatments within the field of immunology and inflammation. As we've covered on the call, there are several important milestones we expect to occur over the next few quarters, which we believe present significant opportunities to create value for our shareholders. This is highlighted by the SAD/MAD top-line results from the ongoing FRTX-02 phase I study, which remain on track to be announced in early 2023, and the continued development of our other novel therapeutic candidates, notably our lead STING inhibitor, FRTX-10. This concludes today's prepared remarks. I'll now ask the operator to open the call up for questions. Operator? Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star then one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star then two if you would like to remove your question from the queue. For participants using speak equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. Our first question is from Tim Lugo of William Blair. Please go ahead. Thank you for taking the question, and congratulations on the progress. For part two of the FRTX-02 trial, can you discuss kind of the therapies in the moderate AD patients, which they've been exposed to prior to entering the trial? I assume these are going to be biologic naive patients, but can you give us kind of a sense of how pretreated they'll be? Sure. Hey, thanks, Tim, for the question. Monica, why don't I turn that one over to you? Sure. Hi, Tim. Actually, we're making requirements for patients not to have received biologics such as dupilumab for a period of six months prior to entering the study. For any previous biologic, we'll make sure that it's far beyond the half-life to make sure there's no continued activity of that drug. Their previous use does not exclude them from participating in this part one piece of the study, phase one part of the study. Any thoughts around JAK inhibitors as an exclusion or, you know, will these be probably JAK inhibitor-naive patients? These will most likely be JAK inhibitor-naive patients, but we do have an exclusion for the period to which they would be prohibited in advance of Okay, great. Maybe kind of a broader question, Rob. Can you just discuss, you know, your thoughts around business development of both of the, you know, the two lead novel assets when, you know, obviously you'll want some proof of concept data, but, you know, in your opinion, kind of when's the ideal time to seek a partner or, you know, or how long do you kinda wanna continue development alone without a partner? Yeah, it's good. You know, good question, Tim. Obviously, this is more of an art than a certainty on when you do these things. Obviously, you'd like to have good data to talk to people about. You know, we do get regular requests really ever since we acquired both the STING inhibitor as well as the DYRK1A. You know, we listen to those. We share the information we can with parties. Obviously we also are out talking to investors. We're kind of using a multi-pronged approach here. I don't know if there is an ideal time. I think it's a combination of the drug, you know, the data you have on the drug, as well as, you know, the company's position at that time. There's been obviously a major market dislocation over the past year. Can you maybe speak to that? You know, when you're approached by these companies in terms of a development partnership, I assume, you know, maybe even upfront could be significantly larger than, you know, what the kind of market is giving you these days? Yeah. We have lots of companies that have approached us, kind of small, medium, and large, that are curious and interested in both of these platforms, actually. I don't think I really wanna speak to what a deal might look like, because, you know, obviously we don't have one that we're ready to announce, and therefore it's probably not appropriate to speak on that. Certainly we're encouraged by their interest and their curiosity in the mechanism being first in class, you know, with the DYRK1A is intriguing to people. They're curious about the mechanism and understand why we acquired it and are excited to see more data as we move it forward. Understood. Thank you. Our next question is from Thomas Flaten of Lake Street Capital. Please go ahead. Hey, guys. Appreciate you taking the question. Kinda back to the prior questions around partnership, do you have enough ability to differentiate the DYRK assets so that you can license on a compound by compound basis? Or do you think it'll be more of a platform type deal? I don't know how much work you've done. I guess that's what I'm trying to get at. Yeah, I mean, Yeah, Thomas, I think it depends, right, on what type of partnership it is. Certainly, you know, in this library of assets that we acquired, there are those that cross the blood-brain barrier, versus those that don't. Our belief is, at least from some of the, you know, the broad research that's out there on DYRK1A, that there may be opportunities for these kind of products in a disease like Alzheimer's disease, for example, where you'd need to have that blood-brain barrier penetration. Not sure you'd want that otherwise. We do see where you might be able to break these up. They've also, you know, there's also different families that are involved in this in terms of, you know, where the, how the products were originally developed. There are a couple different ways we could choose to do that. It all depends on the party, what they're interested in and certainly, you know, what they might be offering. This is a bit of a hypothetical on a hypothetical, but given how crowded and competitive the AD market is, for example, when you guys are thinking about biomarkers, are you thinking about. I'm just curious how you're thinking about those kind of from a response recognition all the way through to something that could be used for, you know, value-based contracting. I'm just curious how comprehensive that thought process is or how you guys are factoring that into the studies, 'cause I realize you're already collecting biomarkers in the ongoing study. Yeah. A couple things there. One is, remember, it's important that we've always said that although we're gonna do this first study in patients in AD, it isn't necessarily where we're gonna go. It's just a really useful treatment to understand the drug and understand how it's impacting someone with autoimmune diseases. So we'll be able to read an awful lot in that because it's skin, you know, it's easier to do that. It also, you know, we have four weeks, so we think we'll be able to potentially see efficacy easier in that first four weeks in an atopic dermatitis patient. All that information will be what leads us to decide where we go in phase II. It isn't certain that it's gonna be an AD. The biomarkers we're looking for are broader so that we can also have an understanding of other potential autoimmune diseases. In terms of their ability from a payer point of view, it's a little early for that one in terms of a value message. We'll leave that one to rest for now. Monica, was there anything else that you'd like to add to my superficial summary? No, I think that was pretty accurate. Obviously, some of it depends on what we're going to see from these biomarkers. At this point, we'll be looking at markers for assuring ourselves that we have engagement of the target that we believe we're engaging and also looking at markers within the disease. Again, I just wanna stress this is a four-week study, so it is limited. We've said that there's going to be assessment of preliminary efficacy intentionally, because of the time allowed. So some of these biomarkers will be able to provide information within this short period. Some of them we'll still have to study in the next study. So I think it's going to be in evolution as we move forward. Understood. Thanks for taking the questions. Much appreciated. Thank you. We have no further questions at this time. I would like to turn the floor back over to Robert Brown for closing comments. Please go ahead, sir. Thanks for taking the time this afternoon to listen to our update. We're enthused about what the future holds for Fresh Tracks as a biotech exploring cutting-edge treatment alternatives for patients suffering from debilitating autoimmune and inflammatory conditions. We look forward to sharing additional updates on our development progress moving forward. As always, feel free to reach out to us anytime if you have further questions. Have a great day. That concludes today's conference. Thank you for joining us. You may now disconnect your lines.